Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Understanding the Treatment Details for thyroid cancer is essential for patients and families navigating this diagnosis. Liv Hospital combines cutting‑edge technology with a multidisciplinary team to deliver personalized care that meets the needs of international patients. Each year, thyroid cancer accounts for roughly 2% of all new cancer cases worldwide, and early, precise intervention dramatically improves outcomes. This page outlines every step of the therapeutic journey—from initial assessment and imaging to surgical options, radioactive iodine therapy, targeted medicines, and long‑term follow‑up—so you can make informed decisions about your health.
Our comprehensive approach begins with a thorough diagnostic workup, ensuring that the chosen treatment aligns with the tumor’s type, stage, and genetic profile. Whether you are considering traditional surgery, minimally invasive techniques, or newer systemic therapies, Liv Hospital’s international patient services streamline appointments, transportation, interpreter support, and accommodation, allowing you to focus on recovery.
Below, you will find detailed sections that explain each therapeutic modality, potential side effects, and the support structures in place to guide you through every phase of care.
Thyroid cancer is not a single disease; it comprises several histological subtypes, each with distinct biological behavior and treatment implications. The most common forms include papillary carcinoma (≈80% of cases), follicular carcinoma, medullary carcinoma, and the more aggressive anaplastic carcinoma. Accurate classification begins with fine‑needle aspiration biopsy, followed by molecular testing when indicated.
Staging follows the American Joint Committee on Cancer (AJCC) TNM system, which evaluates tumor size (T), regional lymph node involvement (N), and distant metastasis (M). Early-stage (I–II) papillary cancers often have an excellent prognosis, while advanced stages (III–IV) may require multimodal therapy.
Understanding these nuances allows clinicians to tailor the treatment details to each patient’s unique disease profile, optimizing both efficacy and quality of life.
Before any therapeutic intervention, a comprehensive diagnostic workup establishes a clear roadmap. The process typically includes:
Liv Hospital’s radiology department utilizes high‑resolution ultrasound and state‑of‑the‑art cross‑sectional imaging to create three‑dimensional maps of the thyroid gland and surrounding structures. Multidisciplinary tumor board meetings review each case, ensuring that the subsequent treatment details reflect the most current evidence‑based guidelines.
Surgery remains the cornerstone of curative therapy for most thyroid cancers. The choice between total thyroidectomy, lobectomy, or minimally invasive approaches depends on tumor size, location, and patient preference.
Total thyroidectomy removes the entire gland and is recommended for tumors larger than 1 cm, bilateral disease, or when postoperative radioactive iodine therapy is planned. Lobectomy (hemithyroidectomy) may be sufficient for low‑risk, unifocal papillary cancers ≤1 cm, preserving thyroid function and reducing the need for lifelong hormone replacement.
Minimally invasive options include:
Liv Hospital’s surgical team is experienced in both open and robotic techniques, selecting the approach that balances oncologic completeness with cosmetic outcomes. Intraoperative nerve monitoring reduces the risk of recurrent laryngeal nerve injury, while meticulous parathyroid preservation minimizes postoperative hypocalcemia.
After thyroidectomy, many patients benefit from radioactive iodine (RAI) therapy, which targets residual thyroid tissue and microscopic disease. RAI utilizes I‑131, a beta‑emitting isotope that is selectively taken up by thyroid cells.
Key considerations for RAI include:
Potential side effects are generally mild and transient, such as dry mouth, altered taste, or temporary nausea. Long‑term risks, including salivary gland dysfunction or secondary malignancies, are rare when appropriate dosing guidelines are followed.
Liv Hospital’s nuclear medicine department provides individualized dosimetry, strict radiation safety protocols, and comfortable isolation facilities for patients receiving high‑dose RAI, ensuring both efficacy and safety.
For patients with radioactive‑iodine‑refractory disease, metastatic spread, or aggressive histologies (e.g., medullary or anaplastic carcinoma), systemic therapies become essential. Recent advances have introduced several FDA‑approved agents tailored to molecular alterations.
Common targeted options include:
Immunotherapy, particularly pembrolizumab, is under investigation for tumors with high microsatellite instability or PD‑L1 expression. Treatment selection is guided by comprehensive genomic profiling performed at Liv Hospital’s molecular pathology laboratory.
Side‑effect management—ranging from hypertension and hand‑foot syndrome to fatigue and dermatologic reactions—is integrated into a supportive care pathway, ensuring patients maintain quality of life while receiving aggressive therapy.
Successful treatment concludes with a structured follow‑up plan designed to detect recurrence early and address survivorship needs. Standard protocols involve:
Liv Hospital offers a dedicated International Patient Services team that assists with visa arrangements, airport transfers, language interpretation, and accommodation near the hospital. Nutrition counseling, physiotherapy, and psychosocial support are also available to promote holistic recovery.
Patients are encouraged to engage in regular physical activity, maintain a balanced diet rich in iodine‑containing foods (unless contraindicated), and attend survivorship workshops that address long‑term endocrine management and mental well‑being.
Liv Hospital is a JCI‑accredited, internationally recognized center that combines world‑class oncology expertise with a seamless patient‑centric experience. Our multidisciplinary teams include thyroid surgeons, endocrinologists, nuclear medicine specialists, and molecular pathologists who collaborate to design individualized treatment details for each case. International patients benefit from 360‑degree support—from visa assistance and airport pickup to interpreter services and comfortable lodging—allowing you to focus solely on healing.
Ready to discuss your personalized thyroid cancer plan? Contact Liv Hospital today to schedule a virtual consultation and take the first step toward comprehensive, compassionate care.
Liv Hospital Ulus
Assoc. Prof. MD. Evrim Duman
Radiation Oncology
Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam
Medical Oncology
Liv Hospital Ulus
Prof. MD. Duygu Derin
Medical Oncology
Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda
Radiation Oncology
Liv Hospital Ulus
Prof. MD. Meral Günaldı
Medical Oncology
Liv Hospital Vadistanbul
Assoc. Prof. MD. Murat Ayhan
Medical Oncology
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Erkan Kayıkçıoğlu
Medical Oncology
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez
Gynecological Oncology
Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan
Medical Oncology
Liv Hospital Bahçeşehir
MD. Taylan Bükülmez
Radiation Oncology
Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter
Gynecological Oncology
Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan
Medical Oncology
Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan
Medical Oncology
Liv Hospital Topkapı
Assoc. Prof. MD. Emir Çelik
Medical Oncology
Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı
Medical Oncology
Liv Hospital Topkapı
Prof. MD. İrfan Çiçin
Medical Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan
Gynecological Oncology
Liv Hospital Ankara
Prof. MD. Fikret Arpacı
Medical Oncology
Liv Hospital Ankara
Prof. MD. Gökhan Erdem
Medical Oncology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap
Medical Oncology
Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu
Medical Oncology
Liv Hospital Ankara
Spec. MD. Ender Kalacı
Medical Oncology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Liv Hospital Gaziantep
Prof. MD. Fatih Teker
Medical Oncology
Liv Bona Dea Hospital Bakü
Spec. MD. ELXAN MEMMEDOV
Medical Oncology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elkhan Mammadov
Medical Oncology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Spec. MD. Natavan Azizova
Medical Oncology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Papillary carcinoma accounts for about 80% of cases and usually has an excellent prognosis, especially when detected early (stage I‑II). Follicular carcinoma can spread to lungs or bone via the bloodstream. Medullary carcinoma arises from C cells and may be linked to genetic syndromes, while anaplastic carcinoma is rare and aggressive, requiring urgent systemic therapy. Staging follows the AJCC TNM criteria: T describes tumor size and local extension, N indicates regional lymph node involvement, and M denotes distant metastasis. Early-stage disease often requires only surgery, whereas advanced stages may need multimodal treatment including radioactive iodine or targeted therapies.
The diagnostic workup starts with a neck ultrasound to assess nodule characteristics and cervical lymph nodes. Fine‑needle aspiration (FNA) provides cytologic diagnosis, distinguishing benign from malignant lesions. Thyroid function tests (TSH, T3, T4) evaluate hormonal status. A radioactive iodine scan determines tumor iodine avidity, guiding suitability for RAI therapy. Advanced imaging (CT, MRI, PET‑CT) detects extrathyroidal extension or distant metastases, which is crucial for accurate staging and treatment planning. All results are reviewed in a multidisciplinary tumor board to formulate a personalized treatment plan.
Total thyroidectomy removes the entire gland, providing the best chance for complete disease removal and allowing for effective postoperative radioactive iodine (RAI) treatment. It is indicated for tumors >1 cm, multifocal or bilateral disease, and aggressive histologies. Lobectomy (hemithyroidectomy) preserves thyroid function and avoids lifelong hormone replacement, making it appropriate for low‑risk, solitary papillary cancers ≤1 cm without evidence of spread. The decision also considers patient preference, cosmetic outcomes, and potential surgical risks such as recurrent laryngeal nerve injury or hypocalcemia.
After total thyroidectomy, patients may receive I‑131, a beta‑emitting isotope that selectively accumulates in thyroid cells due to their iodine‑transport mechanisms. Prior to RAI, the patient’s TSH level is raised (≥30 mIU/L) either by hormone withdrawal or recombinant TSH to enhance iodine uptake. Dosimetry calculates the optimal activity (30–150 mCi) based on disease burden. Post‑treatment whole‑body scans assess iodine distribution and identify metastatic sites. Side effects are usually mild, such as dry mouth or nausea, while long‑term risks like secondary malignancies are rare when dosing follows guidelines.
For radioactive‑iodine‑refractory differentiated thyroid cancer, lenvatinib and sorafenib (tyrosine kinase inhibitors) have shown efficacy in prolonging progression‑free survival. Medullary thyroid carcinoma with RET mutations responds to selective RET inhibitors such as selpercatinib and pralsetinib. Anaplastic thyroid cancer harboring BRAF‑V600E mutations can be treated with a combination of BRAF inhibitors (vemurafenib or dabrafenib) and MEK inhibitors (trametinib). Pembrolizumab, an immune checkpoint inhibitor, is being studied for tumors with high microsatellite instability or PD‑L1 expression. Treatment choice is guided by comprehensive genomic profiling, and side‑effect management is integrated into patient care.
BlogCancerFeb 19, 2026Thyroid cancer often starts without any symptoms. Most early cases don’t show any signs. The first si...
BlogCancerFeb 19, 2026Many people with thyroid cancer wonder if they need chemotherapy. The good news is that chemotherapy is not...
BlogCancerFeb 19, 2026Thyroid cancer is one of the most treatable forms of cancer. When caught early, it has a high survival rate...
BlogCancerFeb 19, 2026Thyroid cancer can be a silent disease, often growing slowly without noticeable symptoms. Many people live ...
BlogCancerFeb 19, 2026Stage1 thyroid cancer often doesn’t show symptoms early on. This makes it hard to catch it right away...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75